

405 Concord Avenue #352, Belmont, MA 02478

617-977-4304

info@ Ispa.org

www.lspa.org

PFAS Due Diligence and Understanding Stakeholders' Risk Considerations

March 12, 2025 from 10:00 AM – 12:30 PM via Zoom

The course will begin with a discussion of the timeline of regulatory changes affecting PFAS findings in due diligence, followed by a discussion of evaluating PFAS-related risks based on potential sources, suspected pathways, and area groundwater use. The course will then discuss specific research methods used to evaluate the potential for PFAS-related findings, including their advantages and drawbacks, followed by a discussion of potential next steps following the identification of PFAS-related findings. Finally, the course will discuss understanding stakeholders' risk considerations, including risks to on- and off-site human receptors; transactional risks; regulatory risks; and litigation risks. Throughout both presentations, the course will examine case studies of properties where PFAS-related findings were identified.

Part 1: PFAS in Due Diligence (Genevieve Reynolds)

- 10:00 Timeline of regulatory changes affecting PFAS findings in due diligence
- 10:05 Discussion of ASTM E 1527-21, how the standard defines "likely" and "hazardous substances," and how this affects PFAS-related findings
 - Breakdown of VERTEX's findings on recent ESAs how many sites actually have PFAS-related concerns?
- 10:15 Evaluating PFAS-related risks in Due Diligence
 - Source/Pathway model, flow chart, and radar chart
 - Illustrative case studies
- 10:30 Researching PFAS in Due Diligence
 - Review of specific research methods and sources, including databases, historical sources, interviews, local research, and more
 - Illustrative case studies
- 10:55 Detailed Case Study
- 11:05 Next Steps
 - Soil disposal options considerations during Due Diligence
 - Groundwater and DPS
- 11:15 Questions & Answers

Part 2: Understanding Stakeholders' Risk Considerations (Elizabeth Mack)

- 11:25 Types of risk presented by PFAS in Due Diligence
 - o Risk to Human Health (on and off-site receptors)
 - Transactional Risk
 - Regulatory Risk
 - Litigation Risk
 - Protection or not through AAI under the Comprehensive Environmental Response,
 Compensation, and Liability Act (CERCLA) Section 101(35)(A)—Phase Is
- 11:45 Further Case Studies: Examples of Risk Analyses and Considerations
- 12:10 Questions & Answers
- 12:30 Wrap-Up and Webinar Adjourns

